Search tips
Search criteria 


Logo of cardiovascresLink to Publisher's site
Cardiovasc Res. 2009 July 15; 83(2): 195–203.
Published online 2009 February 27. doi:  10.1093/cvr/cvp079
PMCID: PMC2701719

Myocardial protection by nitrite


Nitrite has long been considered to be an inert oxidative metabolite of nitric oxide (NO). Recent work, however, has demonstrated that nitrite represents an important tissue storage form of NO that can be reduced to NO during ischaemic or hypoxic events. This exciting series of discoveries has created an entirely new field of research that involves the investigation of the molecular, biochemical, and physiological activities of nitrite under a variety of physiological and pathophysiological states. This has also led to a re-evaluation of the role that nitrite plays in health and disease. As a result there has been an interest in the use of nitrite as a therapeutic strategy for the treatment of acute myocardial infarction. Nitrite therapy has now been studied in several animal models and has proven to be an effective means to reduce myocardial ischaemia–reperfusion injury. This review article will provide a brief summary of the key findings that have led to the re-evaluation of nitrite and highlight the evidence supporting the cardioprotective actions of nitrite and also highlight the potential clinical application of nitrite therapy to cardiovascular diseases.

Keywords: Nitric oxide, Nitrite, Cardioprotection, Myocardial ischaemia, Acute myocardial infarction

1. Introduction

Nitrite is an oxidative breakdown product of nitric oxide (NO) that has traditionally been viewed as an acute marker of NO flux/formation in biological systems.1,2 In this regard, nitrite has long been considered to be an inert by-product of NO metabolism. More recently, nitrite has moved to the forefront of NO biology3,4 with the discovery that it represents an important storage form of NO in blood and tissues that can be readily reduced to NO under certain pathological conditions.5,6 This exciting series of discoveries has established a new field of research that entails the investigation of the molecular, biochemical, and physiological activities of nitrite under a variety of physiological and pathophysiological states.4 Among the most exciting developments in the field of nitrite physiology is the recent finding that nitrite is cytoprotective in a number of animal models of disease, including myocardial ischaemia–reperfusion (I/R) injury. In this review we will provide a brief summary of the key findings that have led to the re-evaluation of the biochemical and physiological role of nitrite, as well as, highlight the most recent evidence supporting the cardioprotective actions of nitrite. Finally, we will also evaluate the therapeutic potential of nitrite therapy for cardiovascular diseases such as acute myocardial infarction (MI), congestive heart failure, and peripheral artery disease.

2. Nitric oxide and cardioprotection

Although the mechanisms of nitrite-mediated cardioprotection have not been fully elucidated, there is a consensus that NO plays a prominent role. Therefore, we will begin this article with a brief historical account of NO and cardioprotection. NO is a member of a family of labile biological mediators termed gasotransmitters.7 It was first discovered in the late-1700s and, for the better part of 200 years, was widely considered to be a toxic gas and environmental hazard.8 The importance of NO in the field of biology and medicine was not fully appreciated until the 1980s when in a series of studies conducted by several independent groups it was discovered that NO is generated in mammals, including humans, by nitric oxide synthases (NOSs) and plays a prominent role in controlling blood pressure via the regulation of vascular tone.9 There are three isoforms of NOS that have been characterized, purified, and cloned: the endothelial isoform (eNOS); the neuronal isoform (nNOS); and the inducible isoform (iNOS). All three isoforms are able to catalyze the production of NO from an assortment of precursors and co-factors, including l-arginine, NADPH, and oxygen.10 The different isoforms of NOS are found in a variety of cell types and tissues, including neuronal cells and the vascular endothelium. The localization of eNOS in the vascular endothelium is of particular importance for cardiovascular physiology, as eNOS maintains basal vascular tone through its release of low levels of NO.11

NO has been extensively studied in the setting of myocardial I/R injury. Previous studies clearly demonstrate that the deficiency of eNOS exacerbates myocardial I/R injury,12,13 whereas the overexpression of eNOS,14,15 the administration of NO donors,16,17 and inhaled NO gas therapy18 all significantly protect the myocardium.19 In terms of its cytoprotective mechanisms, NO possesses a number of physiological properties that makes it a potent cardioprotective-signalling molecule.20 First, NO is a potent vasodilator in the ischaemic myocardium,21 which allows for essential perfusion of injured tissue. Secondly, NO reversibly inhibits mitochondrial respiration.22 The inhibition of mitochondrial respiration during early reperfusion counterintuitively leads to a decrease in mitochondrial-driven injury by extending the zone of adequate tissue cellular oxygenation away from vessels.23 Thirdly, NO is a potent inhibitor of neutrophil adherence to vascular endothelium.24 Neutrophil adherence is an important event initiating further leukocyte activation and superoxide radical generation, which in turn leads to injury to the endothelium and perivascular myocardium.25 Fourth, NO also prevents platelet aggregation,26 which together with the anti-neutrophil actions of NO attenuates capillary plugging.27 Finally, NO inhibits apoptosis28 either directly or indirectly by inhibiting caspase-3-like activation via a cGMP-dependent mechanism and by direct inhibition of caspase-3-like activity through protein S-nitrosylation.29 While the majority of experimental studies investigating the effects of NO-based therapies in myocardial I/R have reported that NO protects the ischaemic myocardium, there have been some studies reporting negative effects of NO. A review by Bolli19 evaluated all of the studies investigating the role of NO in modulating the severity of I/R injury conducted between 1991 and 2001 in the non-preconditioned myocardium. This very through analysis of the literature revealed that 92 experimental studies had been conducted with 73% of all the studies concluding that NO (endogenous or endogenous) is protective while 20% reported no detectable effects, and 12% reported that NO was detrimental.19 A very important consideration when evaluating the efficacy of NO therapies in cardiovascular disease models is the concentration or dose of NO that is investigated. It is now well-appreciated that physiological levels (i.e. nanomolar) of NO promote cytoprotection and suprapharmacological levels (i.e. high micromolar and millimolar) mediate cellular necrosis and apoptosis.

A number of studies have evaluated the cytoprotective signalling pathways activated by NO in various experimental systems including isolated cardiac cells and intact hearts. NO has been shown to activate a number of cellular targets that are linked to cardioprotection, including components of the reperfusion injury salvage kinase pathway, such as protein kinase C (PKC) and Erk1/2.30 NO not only triggers the activation of Janus kinases (JAKs) leading to tyrosine phosphorylation of signal transducers and activators of transcription-1/3 (STAT1/3), but also triggers the activation of a PKC–Raf-1–MEK1/2–Erk1/2 signalling cascade leading to serine phosphorylation of STAT1/3.31 NO has also been shown to directly protect cultured rat neonatal cardiomyocyte mitochondria by modulating mitochondrial Ca2+ handling, which in turn diminishes reoxygenation-associated Ca2+ overload.32,33 Specifically, NO inhibits the activity of L-type Ca2+ channels through S-nitrosylation modifications,34,35 which leads to less SR Ca2+ loading and less Ca2+-induced ischaemic injury.35 In addition, NO prevents cytosolic Ca2+ overload through an increase in sarco(endo)plasmic reticulum Ca2+-ATPase-2a (SERCA2a) activity.36 NO is suggested to also mediate expression of cyclooxygenase 2 (COX-2), which has also been shown to be involved in cardioprotection.37 Furthermore, an increase in NO has been shown to be involved in cardioprotection via activation of protein kinase G (PKG), which leads to activation of mitochondrial pathways including activation of an ATP-regulated mitochondrial channel that allows transport of K+ into the mitochondria (mito KATP channel).38 NO has also been shown to increase S-nitrosylation of complex I of mitochondria,39 which is suggested to alter reactive oxygen species (ROS) generation during ischaemia and/or reperfusion.40

3. Nitrite and cardioprotection

The synthesis of NO is significantly influenced by numerous cofactors such as tetrahydrobiopterin, flavin mononucleotide and flavin adenine dinucleotide, the presence of reduced thiols, and the endogenous NOS inhibitor asymmetric dimethylarginine, as well as, substrate and oxygen availability. During ischaemia, the ability of eNOS to generate NO is severely reduced because of an inadequate delivery of oxygen and co-factors.41 Consequently, investigators have explored alternate means to increase the generation of NO, to increase the half-life of NO, and to prolong the actions of NO in an attempt to limit the extent of I/R injury. This approach has garnered some success, as drugs that positively modulate eNOS function and the NO signalling pathway, such as statins4244 and phosphodiesterase inhibitors (PDE5 inhibitors)4547 have been shown to reduce the severity of myocardial I/R injury. Of late, a great deal of attention has been paid to a seemingly unlikely source that has proven to be an effective means to increase NO levels.

The anion nitrite (NO2) is an endogenous substance produced by the oxidation of NO in aerobic conditions48 and has long been viewed as an indirect determinant of NO synthase activity.49 At physiological ranges of pH and oxygen tension, nitrite has been considered to be a highly stable and inert metabolic end-product of NO oxidation with limited intrinsic biological activity.5052 In addition to the oxidation of NO, nitrite is also derived from reduction of salivary nitrate by commensal bacteria in the mouth and gastrointestinal tract as well as from dietary sources such as meat, vegetables, and drinking water.5355 Although nitrite was generally considered to be an inactive NO metabolite, there were early indications that nitrite could be reduced back to NO under certain conditions (i.e. low pH). In his Nobel Prize Lecture, Furchgott noted that acidified solutions of sodium nitrite surprisingly produced strong transient relaxations of the rabbit aorta much like solutions of NO gas.56 In terms of cardioprotection, it was reported in 1990 that the infusion of acidified sodium nitrite (12.5–50 mmol/kg/h) during myocardial ischaemia significantly reduced I/R injury in cats.57 These studies took advantage of the reducing capacity of the acidified solutions to generate NO from nitrite and in so doing simply created an NO donor. Perhaps, it was the similarities of acidified nitrite to solutions of NO gas and other NO donors, which precluded nitrite from being studied further as a potential source of NO. As such, nitrite remained designated as an inert metabolite of NO until several years ago.

Nitrite has now moved to the forefront of NO biology2 with the discovery that it represents a critical NO storage form in both blood and tissues,58 which can be reduced to NO during ischaemic or hypoxic events (Figure 1).54,5860 The liberated NO exerts biological effects at the level of the endothelium or diffuse into adjacent tissue and render effects through signalling mechanisms at the cellular level. This paradigm shift in nitrite physiology can be attributed to the findings of several key studies. The first set of studies from Zweier's laboratory demonstrated that NO formation increased during myocardial ischaemia independent of enzymatic activity.61 Using electron paramagnetic resonance spectroscopy and chemiluminescence they observed that the generation and accumulation of NO from nitrite increases 100-fold under the acidic and highly reduced conditions of the ischaemic myocardium.59,62 The next set of studies demonstrated that the exogenous administration of nitrite could limit the extent of myocardial injury following ischaemia and reperfusion. Webb et al.48 first reported using a Langendorff isolated heart model that the infusion of nitrite (10 and 100 µM) prior to ischaemia reduced infarct size and was associated with comparable improvements in the recovery of left ventricular function. Duranski et al.52 reported that nitrite was cardioprotective in an in vivo mouse model of myocardial I/R injury. In this study, mice were subjected to 30 min of left coronary artery occlusion followed by 24 h of reperfusion. Sodium nitrite was administered at blood concentrations of 2.4–960 nM during myocardial ischaemia and was found to exert profound dose-dependent protective effects on cellular necrosis, with highly significant protective effects observed at near-physiological blood nitrite concentrations (48 nM). Consistent with hypoxia-dependent nitrite bioactivation, nitrite was reduced to NO, S-nitrosothiols, N-nitrosamines, and iron-nitrosylated haem proteins. Subsequent work has confirmed and expanded on these findings, demonstrating that nitrite therapy initiated at the onset of reperfusion protects the ischaemic myocardium and that nitrite therapy can also precondition the myocardium through either systemic or oral administration.63 Gonzalez et al.64 recently investigated whether a low dose of intravenous nitrite therapy would enhance the efficacy of reperfusion therapy for acute MI in a protocol compatible with typical delays from onset of chest pain to emergent intervention. In this study, they used an in vivo canine model with a protocol of 2 h of coronary artery ischaemia followed by 6 h of reperfusion. Nitrite therapy (0.20 µmol/min/kg) was administered either during the last 60 min of ischaemia or during the last 5 min of ischaemia. They found that nitrite therapy limited MI and apoptosis. Importantly, the mechanism of myocardial protection was found to be independent of the time/ischaemia severity integral because the group infused with nitrite during the last 5 min of ischaemia experienced a reduction in infarct size and apoptosis almost to a similar degree as the 60 min infusion group. This suggests that infusion of nitrite could be initiated prior to percutaneous coronary intervention.64

Figure 1

Predominant pathways for the generation of nitric oxide (NO) from nitrite. Nitrite is formed when NO generated from endothelial nitric oxide synthase reacts with molecular oxygen. Nitrite is then stored in the blood stream and myocardium. During conditions ...

Nitrite therapy has now been studied in a variety of in vitro and in vivo animal models and has proven to be an effective means to reduce I/R injury.6570 However, there are two key questions regarding nitrite therapy that are still not answered. The first question is centred on how nitrite is reduced to NO during ischaemia. Nitrite reductase activity in mammalian tissues has been linked to the mitochondrial electron transport system,7173 non-enzymatic acidic disproportionation,59 deoxyhaemoglobin,74 xanthine oxidase,48,75,76 and more recently myoglobin.77,78 The myoglobin angle is interesting, as it has long been considered a scavenger of NO.79 Secondly, the cytoprotective effects of nitrite therapy have not been fully elucidated. It has been universally shown that nitrite-mediated protection is independent of eNOS and haem oxygenase-1 enzyme activities52 and completely dependent on NO generation, as evidenced by the complete blockage of protection by the NO scavengers 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide (carboxy-PTIO)48 and PTIO.52,63 Therefore, the cytoprotective effects of nitrite therapy are likely similar to those attributed to NO. Indeed, Shiva et al.63 have reported that the reduction of nitrite to NO results in the inhibition of complex I of the mitochondrial transport chain by post-translational S-nitrosation. This dampens electron transfer and effectively reduces ROS generation upon reperfusion and ameliorates oxidative inactivation of complexes II–IV and aconitase, thus preventing mitochondrial permeability transition pore opening and cytochrome c release.

4. Nitrite homeostasis and myocardial injury

Systemic nitrite levels are derived from both endogenous and exogenous sources. As much as 70% of plasma nitrite has been reported to originate from the oxidation of eNOS-derived NO,80 while the remaining 30% of plasma nitrite is derived from the consumption of nitrite and nitrate in dietary sources such as meat, vegetables (especially green leafy vegetables), and drinking water.5355 In general, the dietary component of plasma nitrite is derived from nitrate, as humans do not generally consume significant amounts of nitrite in their diet. Nitrate enters the stomach and then circulates in the blood and is converted into nitrite by commensal bacteria in the mouth and gastrointestinal tract. Both sources of nitrite are important for maintaining steady-state nitrite levels in both the plasma and tissues, such as the heart (Figure 2). Recent data have shown that nitrite derived from either of these sources accumulates in the plasma and is stored in the heart and metabolized into NO during ischaemia.81,82

Figure 2

Nitrite homeostasis is determined by nitric oxide (NO) generation from NO synthases and dietary consumption of nitrate. Nitrate enters the stomach and then circulates in the blood and is converted into nitrite via salivary bacteria containing nitrate ...

Recent data have also shown that dysfunction of either source can result in an exacerbation of injury following myocardial ischaemia.82,83 For example, mice deficient in eNOS (eNOS−/−) exhibit reduced steady-state levels of both plasma and cardiac nitrite levels when compared with wild-type mice,80,83 whereas, transgenic mice with a cardiac-specific overexpression of the human eNOS gene (eNOS-Tg) exhibit higher steady-state levels of both plasma and cardiac nitrite levels when compared with non-transgenic mice.14,81 Predictably, the deficiency of eNOS exacerbates myocardial I/R injury,12,13 whereas the overexpression of eNOS14,15 significantly protects the myocardium against I/R injury. Several studies have reported the benefits of dietary nitrite and nitrate as means to restore or enhance NO homeostasis.83 Bryan et al.82 recently investigated the effects of dietary nitrite and nitrate supplementation and insufficiency in mice on NO homeostasis and on the severity of myocardial I/R injury. In this study mice were fed a standard diet with or without nitrite (50 mg/L) supplemented in their drinking water for 7 days. Mice supplemented with nitrite exhibited significantly higher plasma levels of nitrite, significantly higher heart levels of nitrite and NO metabolites and displayed a 48% reduction in infarct size following myocardial ischaemia–reperfusion. Supplemental nitrate (1 g/L) in the drinking water for 7 days also increased blood and tissue NO products and significantly reduced infarct size. In addition, nitrite was consumed during the ischaemic phase with a concomitant increase in nitroso/nitrosyl products in the heart and plasma, which were restored to baseline levels by 30 min of reperfusion. In contrast, mice fed a diet deficient in nitrite and nitrate for 7 days exhibited significantly diminished plasma and heart levels of nitrite and NO metabolites and a 59% increase in infarct size following myocardial ischaemia–reperfusion.82 This data clearly show that dietary deficiency of nitrite and nitrate mimics the NO homeostasis found in eNOS−/− mice, suggesting that dietary sources of nitrite are just as important as endogenous sources of nitrite. This is supported by the findings of a follow-up study by this same group, which evaluated steady-state nitrite and NO metabolite levels in the plasma and hearts of eNOS−/− supplemented with nitrite (50 mg/L) in their drinking water for 7 days.83 They found that nitrite supplementation restored NO homeostasis in eNOS−/− mice and protected against myocardial I/R injury.

Collectively, these findings demonstrate the influence of eNOS-derived and dietary sources of nitrite on both plasma and myocardial levels of nitrite and NO homeostasis, as well as illustrate the cytoprotective effects of dietary nitrite supplementation and consequences of nitrite deficiency on the pathophysiology of myocardial I/R injury.

5. Nitrite and cardiovascular risk

In terms of nitrite homeostasis and cardiovascular risk, there is a small amount of indirect evidence to suggest that nitrite levels may serve as a predictor of risk for the development of cardiovascular disease. The endothelium plays an integral role in the regulation of vascular tone and blood pressure, platelet activity, leukocyte adhesion, and thrombosis and is intimately involved in the development of atherosclerosis.84 Primary cardiovascular risk factors such as hypertension, hypercholesterolaemia, and diabetes mellitus have all been shown to impair endothelial NO generation from eNOS and promote the severity of cardiovascular disease.8587 Furthermore, coronary artery ischaemia and reperfusion has been shown to independently inhibit eNOS function via increased oxidative stress—an effect that results in pronounced deficiencies in myocardial NO levels.88 Therefore, the loss of NO generation as a result of a dysfunctional vascular endothelium could contribute to the development heart disease.85,89,90 Clinically, it has been shown that circulating levels of NO-related metabolites can serve as predictors of cardiovascular risk. A recent report by Kleinbongard et al.91 demonstrates that plasma nitrite levels progressively decrease with increasing cardiovascular risk. They evaluated intima media thickness and flow-mediated dilatation in patients with or without risk factors and cardiovascular disease and found that patients presenting with reduced flow-mediated dilatation and augmented intima to media thickness had lower levels of plasma nitrite compared with healthy individuals. However, with the exception of this one study, direct evidence is lacking on whether or not nitrite can serve as a reliable predictor for cardiovascular risk.

6. Evidence that nitrite is an endocrine molecule of nitric oxide

Given that NO possess diverse physiological actions and profound cytoprotective effects, it is important to understand its cell-signalling mechanisms. Classically, NO has been considered to be a paracrine-signalling molecule. This classification is based on several factors. First, NO has a very short (<2 ms) half-life in blood, owing to consumption by haemoglobin.9294 Secondly, the half-life of NO within normoxic tissues has been estimated to be <0.1 s with diffusion distances dependent upon oxygen concentrations.95,96 Together, these two factors suggested that the transport of NO to distant sites was problematic. Thirdly, NOS activity has been reported to be highly compartmentalized and intricately regulated.1,97 With the recognition that nitrite is a highly important, readily accessible storage form of NO that can be transported in the circulation, there has been a great deal of speculation that nitrite serves as an endocrine signalling molecule of NO.1 Early evidence that led to the speculation that nitrite serves as a NO transporter and facilitates remote physiological actions came from studies utilizing inhaled NO. In these studies inhaled NO has been shown to (i) increase urinary flow in pigs,98 (ii) decrease systemic vascular resistance in septic dogs,99 (iii) decrease systemic vascular resistance in anaesthetized sheep,100 (iv) increase intestinal blood flow during concurrent NO synthase inhibition or after intestinal I/R injury in cats,101103 (v) prevent forearm vasoconstriction during regional NO synthase inhibition in human volunteers,104,105 (vi) increase contralateral forearm blood flow after infusion of NO solution into ipsilateral forearm in human volunteers,106 and (vii) decrease the size of MI in mice.18 While these studies clearly show that nitrite can act as an NO transporter and facilitate remote physiological actions, one could argue that these studies do not directly demonstrate that nitrite is an endocrine molecule of NO as widely speculated.1 The simple reason is that these studies used exogenous NO as the source of NO. Direct evidence that endogenous NO could act as an endocrine signalling molecule was not shown until recently when Elrod et al.81 reported that endogenously derived NO generated from eNOS is transported in the blood, metabolized in remote organs, and mediates cytoprotection in the setting of I/R injury. Utilizing a transgenic mouse with cardiac-restricted overexpression of eNOS, they found that the overexpression of eNOS in the myocardium resulted in increased levels of nitrite and other NO-metabolites in the circulation and subsequent transport and storage in liver. Importantly, increased tissue stores of nitrite in the liver attenuated hepatic I/R injury through formation of NO and nitroso/nitrosyl products. This report provides direct evidence that endogenously generated NO is capable of exerting endocrine activity via nitrite formation and therefore provides direct evidence supporting the reassessment of the perception that NO is merely a paracrine signalling molecule. It is important to note that the study by Elrod et al.81 also demonstrated similar increases in nitrosothiols in the eNOS transgenic mouse model and the authors suggest that nitrosothiols may be responsible for the cardioprotective actions of NO.

7. Future research considerations

The field of nitrite biology has blossomed over the last decade. Nitrite is no longer considered to be an inert by-product of NO that is only useful as a marker for NO. Rather, it is now widely accepted and appreciated that nitrite is a physiologically relevant storage form of NO in blood and tissues that represents an alternate means for the generation of NO during certain pathological situations. Moving forward, the nitrite field faces some important questions that need to be addressed. First, other NO-related metabolites, such as nitrosothiols (RXNOs) have been shown to mirror nitrite in its effectiveness to promote cardioprotection and predict cardiovascular health.14,8183 Heiss et al.107 reported that the plasma pool of RXNOs are depleted in patients with cardiovascular risk factors and S-nitrosothiols (RSNOs) have been shown to be protective in the setting of I/R injury.52,108 Furthermore, there is evidence to suggest that RSNOs may also serve as endocrine molecules of NO.81,109,110 So, the question then becomes, is nitrite or are RXNOs the main endogenous storage form of NO or are both equally important? Secondly, the means by which nitrite is transported from the circulation into tissues has not been identified. Thirdly, the primary nitrite reductase responsible for reducing nitrite to NO during myocardial ischaemia has not been identified. However, myoglobin has recently emerged as the main candidate. Although the primary function of myoglobin has been considered to be cellular oxygen storage and supply, recent studies have suggested classifying myoglobin as a multifactorial allosteric enzyme.79,111,112 In terms of NO biology, myoglobin has long been considered a scavenger of NO.79 Challenging this notion are two recent studies, which demonstrate that under conditions of hypoxia, myoglobin becomes the major nitrite reductase present in the myocardium.77,78 In these studies, it was demonstrated that the NO generated from nitrite by myoglobin escapes autocapture and regulates hypoxic mitochondrial respiration. Thus, the NO formed from nitrite reduction can inhibit respiring mitochondria to conserve tissue oxygen allowing for the diffusion of oxygen deeper into tissue (extension of oxygen gradients) and in the process protect the myocardium.78

There is no doubt that the field of nitrite biology and chemistry is an exciting area of research that continues to challenge the way we view the role that this small molecule plays in NO biology.

8. Clinical application of nitrite therapy to cardiovascular disease

A direct result of our improved understanding of the biochemical conversion of nitrite to NO under both physiological and pathophysiological conditions have been a growing interest in the use of nitrite therapy to treat cardiovascular disease states. At present there are eight clinical studies underway ( to investigate the potential vasculoprotective and cardioprotective actions of acute nitrite therapy in persons with cardiovascular risk factors or cardiovascular disease. Clinical trials are currently underway to evaluate the effects of nitrite therapy on pulmonary hypertension, preconditioning for ischaemic stress, vasodilator therapy, arterial hypertension, and sickle cell disease. The results of these ongoing clinical trials will provide very important insights into the potential clinical benefits of acute intravenous nitrite therapy as well as the effects of inhalation of sodium nitrite solutions.

There are a number of advantages to using sodium nitrite over authentic NO gas or NO donor agents to treat cardiovascular diseases. Sodium nitrite is a highly stable compound that only releases NO under conditions of ischaemia, hypoxia, or low pH and therefore cardiovascular therapy with nitrite could be preferentially targeted to ischaemic or hypoxic tissues and reduce the risk of systemic hypotension. Furthermore, nitrite can be administered via inhalation, intravenous injection, intraperitoneal injection, and orally with NO only being released following the bioconversion of nitrite to NO in the circulation or ischaemic tissues. This is a tremendous advantage with sodium nitrite and is clearly not the case with NO gas or NO donors that spontaneously release NO and have limited routes of administration. It is conceivable that novel sodium nitrite formulations such as transdermal or subcutaneous preparations could be developed to promote local angiogenesis and wound healing in patients with impaired circulation such as diabetics. Finally, since sodium nitrite has been used for many years as part of the cyanide antidote kit in humans there is a wealth of clinical data to support the safety of very high doses of sodium nitrite in critically ill patients. No such data exists for NO gas and NO donors.

Given the very robust preclinical data regarding the cytoprotective effects of intravenous and dietary nitrite in I/R injury syndromes it is very logical to consider clinical trials of sodium nitrite therapy for acute MI, stroke, cerebral vasospasm, as well as an adjunctive therapy for transplantation of various organs. Given that oral administration of nitrite (i.e. dietary nitrite) mimics the cytoprotective actions of intravenous nitrite it would be possible to evaluate either acute intravenous nitrite or more chronic nitrite therapy following oral administration of sodium nitrite. Furthermore, since it has been reported that both oral and intraperitoneal administration of nitrite results in pharmacological preconditioning63 of the myocardium it would also be possible to administer nitrite 24 h prior to organ transplantation surgery, cardiac surgery, and balloon angioplasty procedures to precondition the patient against reperfusion injury.

A recent study by Kumar et al.113 is the first to demonstrate that chronic sodium nitrite therapy promotes vascular angiogenesis in a murine model system of hind-limb ischaemia. This study very clearly demonstrates that nitrite administered intravenously restores ischaemic hind-limb blood flow, stimulates endothelial cell proliferation, and stimulates angiogenesis in an NO-dependent manner. Injection of nitrite resulted in increased tissue nitrite levels, as well as nitrosothiol levels (SNO and XNO) in the ischaemic hind-limb. Furthermore, the pro-angiogenic actions of sodium nitrite were abrogated when an NO-scavenger agent (i.e. C-PTIO) was administered providing further evidence that these effects were largely NO-mediated. This study provides strong support that nitrite can undergo bioconversion to NO in ischaemic tissues and promote cell survival as well as vasculogenesis. The study by Kumar and coworkers provide a very strong impetus for the clinical investigation of sodium nitrite as a potential therapy for peripheral artery disease as well as therapy for chronic myocardial ischaemia and congestive heart failure. The future translation of nitrite from bench to bedside will certainly prove to be an exciting time in cardiovascular medicine and further insights gained from pre-clinical investigations will likely provide evidence for the investigation of various forms of sodium nitrite for other clinical conditions.

Despite the overwhelming enthusiasm for the clinical development of sodium nitrite for the treatment of cardiovascular disease it is very important to proceed with caution. There is a general agreement that very high levels of NO can promote tissue injury, decrease blood pressure, and cardiac performance all of which are contraindicated during any cardiovascular disease condition. Thus, it is extremely important to consider the timing of administration as well as the dosing when dealing with nitrite or any other agents that augment NO bioavailability. Finally, one must also consider the possible drug interactions between nitrite-based therapies and other agents to further avoid potential toxic side-effects.

Conflict of interest: D.J.L. is a participant of a pending U.S. patent filed on 14 October 2003 (patent no. 60/511244) regarding the use of sodium nitrite in cardiovascular disease. D.J.L. is a participant of a pending U.S. patent filed on 15 November 2007 (patent no. 61/003150) regarding the use of nitrite salts in chronic ischaemia.


The National Institutes of Health (2 RO1 HL-060849-09 to D.J.L.) and the National Institutes of Health (F32 DK 077380-01 to J.W.C.), funds from the Carlyle Fraser Heart Center of Emory Crawford Long Hospital.


1. Gladwin MT, Raat NJ, Shiva S, Dezfulian C, Hogg N, Kim-Shapiro DB, et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol. 2006;291:H2026–H2035. [PubMed]
2. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S, et al. The emerging biology of the nitrite anion. Nat Chem Biol. 2005;1:308–314. [PubMed]
3. Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res. 2007;75:327–338. [PMC free article] [PubMed]
4. Lefer DJ. Nitrite therapy for protection against ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2006;290:F777–F778. [PubMed]
5. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156–167. [PubMed]
6. Sinha SS, Shiva S, Gladwin MT. Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation. Trends Cardiovasc Med. 2008;18:163–172. [PubMed]
7. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–935. [PubMed]
8. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006;355:2003–2011. [PubMed]
9. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep. 1999;19:51–71. [PubMed]
10. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146–2152. [PMC free article] [PubMed]
11. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87–104. [PubMed]
12. Sharp BR, Jones SP, Rimmer DM, Lefer DJ. Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol. 2002;282:H2422–H2426. [PubMed]
13. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D, et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol. 1999;276:H1567–H1573. [PubMed]
14. Elrod JW, Greer JJ, Bryan NS, Langston W, Szot JF, Gebregzlabher H, et al. Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2006;26:1517–1523. [PubMed]
15. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2004;286:H276–H282. [PubMed]
16. Pabla R, Buda AJ, Flynn DM, Blesse SA, Shin AM, Curtis MJ, et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res. 1996;78:65–72. [PubMed]
17. Siegfried MR, Carey C, Ma XL, Lefer AM. Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am J Physiol. 1992;263:H771–H777. [PubMed]
18. Hataishi R, Rodrigues AC, Neilan TG, Morgan JG, Buys E, Shiva S, et al. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;291:H379–H384. [PubMed]
19. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001;33:1897–1918. [PubMed]
20. Lefer DJ. Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion. New Horiz. 1995;3:105–112. [PubMed]
21. Johnson G, III, Tsao PS, Lefer AM. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit Care Med. 1991;19:244–252. [PubMed]
22. Loke KE, Laycock SK, Mital S, Wolin MS, Bernstein R, Oz M, et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation. 1999;100:1291–1297. [PubMed]
23. Thomas DD, Liu X, Kantrow SP, Lancaster JR., Jr The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci USA. 2001;98:355–360. [PubMed]
24. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res. 1993;72:403–412. [PubMed]
25. Palazzo AJ, Jones SP, Girod WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol. 1998;275:H2300–H2307. [PubMed]
26. Walter U, Gambaryan S. Roles of cGMP/cGMP-dependent protein kinase in platelet activation. Blood. 2004;104:2609. [PubMed]
27. Calvert JW, Lefer DJ. Statin therapy and myocardial no-reflow. Br J Pharmacol. 2006;149:229–231. [PMC free article] [PubMed]
28. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem. 1999;274:17325–17333. [PubMed]
29. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem. 1997;272:31138–31148. [PubMed]
30. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation. 2007;116:535–544. [PMC free article] [PubMed]
31. Bolli R, Dawn B, Xuan YT. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2003;13:72–79. [PubMed]
32. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69:164–177. [PubMed]
33. Rakhit RD, Mojet MH, Marber MS, Duchen MR. Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reoxygenation in isolated neonatal cardiomyocytes. Circulation. 2001;103:2617–2623. [PubMed]
34. Hu H, Chiamvimonvat N, Yamagishi T, Marban E. Direct inhibition of expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors. Circ Res. 1997;81:742–752. [PubMed]
35. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E. Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ Res. 2006;98:403–411. [PubMed]
36. Rickover O, Zinman T, Kaplan D, Shainberg A. Exogenous nitric oxide triggers classic ischemic preconditioning by preventing intracellular Ca2+ overload in cardiomyocytes. Cell Calcium. 2008;43:324–333. [PubMed]
37. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res. 2003;92:741–748. [PubMed]
38. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res. 2005;97:329–336. [PubMed]
39. Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS. Direct evidence for S-nitrosation of mitochondrial complex I. Biochem J. 2006;394:627–634. [PubMed]
40. Murphy E, Steenbergen C. Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail Rev. 2007;12:293–300. [PubMed]
41. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000;89:160–167. [PubMed]
42. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178–184. [PubMed]
43. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J. 2001;15:1454–1456. [PubMed]
44. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, III, Trocha SD, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 2001;103:2598–2603. [PubMed]
45. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol. 2007;292:H342–H347. [PubMed]
46. Kukreja R, Salloum F, Xi L. Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart. Int J Impot Res. 2007;19:226–227. [PubMed]
47. Kukreja RC, Ockaili R, Salloum F, Xi L. Sildenafil-induced cardioprotection in rabbits. Cardiovasc Res. 2003;60:700–701. author reply 702–703. [PubMed]
48. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA. 2004;101:13683–13688. [PubMed]
49. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta. 1999;1411:273–289. [PubMed]
50. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA. 2001;98:12814–12819. [PubMed]
51. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T, et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol. 2005;1:290–297. [PubMed]
52. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005;115:1232–1240. [PMC free article] [PubMed]
53. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med. 2004;37:395–400. [PubMed]
54. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol. 2005;25:915–922. [PubMed]
55. Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol. 2004;2:593–602. [PubMed]
56. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep. 1999;19:235–251. [PubMed]
57. Johnson G, III, Tsao PS, Mulloy D, Lefer AM. Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Ther. 1990;252:35–41. [PubMed]
58. Bryan NS. Nitrite in nitric oxide biology: cause or consequence? A systems-based review. Free Radic Biol Med. 2006;41:691–701. [PubMed]
59. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med. 1995;1:804–809. [PubMed]
60. Bryan NS, Rassaf T, Maloney RE, Rodriguez CM, Saijo F, Rodriguez JR, et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci USA. 2004;101:4308–4313. [PubMed]
61. Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta. 1999;1411:250–262. [PubMed]
62. Samouilov A, Kuppusamy P, Zweier JL. Evaluation of the magnitude and rate of nitric oxide production from nitrite in biological systems. Arch Biochem Biophys. 1998;357:1–7. [PubMed]
63. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L, et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 2007;204:2089–2102. [PMC free article] [PubMed]
64. Gonzalez FM, Shiva S, Vincent PS, Ringwood LA, Hsu LY, Hon YY, et al. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation. 2008;117:2986–2994. [PMC free article] [PubMed]
65. Baker JE, Su J, Fu X, Hsu A, Gross GJ, Tweddell JS, et al. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels. J Mol Cell Cardiol. 2007;43:437–444. [PMC free article] [PubMed]
66. Lu P, Liu F, Yao Z, Wang CY, Chen DD, Tian Y, et al. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int. 2005;4:350–355. [PubMed]
67. Jung KH, Chu K, Ko SY, Lee ST, Sinn DI, Park DK, et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke. 2006;37:2744–2750. [PubMed]
68. Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Mazzon E, et al. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol. 2007;18:570–580. [PubMed]
69. Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA. 2005;293:1477–1484. [PubMed]
70. Tsuchiya K, Kanematsu Y, Yoshizumi M, Ohnishi H, Kirima K, Izawa Y, et al. Nitrite is an alternative source of NO in vivo. Am J Physiol Heart Circ Physiol. 2005;288:H2163–H2170. [PubMed]
71. Walters CL, Casselden RJ, Taylor AM. Nitrite metabolism by skeletal muscle mitochondria in relation to haem pigments. Biochim Biophys Acta. 1967;143:310–318. [PubMed]
72. Reutov VP, Sorokina EG. NO-synthase and nitrite-reductase components of nitric oxide cycle. Biochemistry (Mosc) 1998;63:874–884. [PubMed]
73. Kozlov AV, Staniek K, Nohl H. Nitrite reductase activity is a novel function of mammalian mitochondria. FEBS Lett. 1999;454:127–130. [PubMed]
74. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498–1505. [PubMed]
75. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation. J Biol Chem. 2004;279:16939–16946. [PubMed]
76. Alikulov ZA, L'Vov NP, Kretovich VL. [Nitrate nitrite reductase activity of milk xanthine oxidase] Biokhimiia. 1980;45:1714–1718. [PubMed]
77. Rassaf T, Flogel U, Drexhage C, Hendgen-Cotta U, Kelm M, Schrader J. Nitrite reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res. 2007;100:1749–1754. [PubMed]
78. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, et al. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res. 2007;100:654–661. [PubMed]
79. Brunori M. Nitric oxide moves myoglobin centre stage. Trends Biochem Sci. 2001;26:209–210. [PubMed]
80. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003;35:790–796. [PubMed]
81. Elrod JW, Calvert JW, Gundewar S, Bryan NS, Lefer DJ. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA. 2008;105:11430–11435. [PubMed]
82. Bryan NS, Calvert JW, Elrod JW, Gundewar S, Ji SY, Lefer DJ. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2007;104:19144. [PubMed]
83. Bryan NS, Calvert JW, Gundewar S, Lefer DJ. Dietary nitrite restores NO homeostasis and is cardioprotective in endothelial nitric oxide synthase-deficient mice. Free Radic Biol Med. 2008;45:468–474. [PMC free article] [PubMed]
84. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673–2678. [PubMed]
85. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844. [PubMed]
86. Harrison DG. Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding? J Clin Invest. 1993;91:1–2. [PMC free article] [PubMed]
87. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14–E22. [PubMed]
88. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol. 1993;33:71–90. [PubMed]
89. Lefer AM, Ma XL, Weyrich A, Lefer DJ. Endothelial dysfunction and neutrophil adherence as critical events in the development of reperfusion injury. Agents Actions Suppl. 1993;41:127–135. [PubMed]
90. Lefer DJ, Lefer AM. Nitric oxide homeostasis control as therapy for cardiovascular diseases. Cardiovasc Res. 1993;27:2282. [PubMed]
91. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006;40:295–302. [PubMed]
92. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265–9269. [PubMed]
93. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526. [PubMed]
94. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR., Jr Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709–18713. [PubMed]
95. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res. 1990;66:1561–1575. [PubMed]
96. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol. 2006;46:235–276. [PubMed]
97. Sessa WC. eNOS at a glance. J Cell Sci. 2004;117:2427–2429. [PubMed]
98. Troncy E, Francoeur M, Salazkin I, Yang F, Charbonneau M, Leclerc G, et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br J Anaesth. 1997;79:631–640. [PubMed]
99. Quezado ZM, Natanson C, Karzai W, Danner RL, Koev CA, Fitz Y, et al. Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol. 1998;84:107–115. [PubMed]
100. Takahashi Y, Kobayashi H, Tanaka N, Sato T, Takizawa N, Tomita T. Nitrosyl hemoglobin in blood of normoxic and hypoxic sheep during nitric oxide inhalation. Am J Physiol. 1998;274:H349–H357. [PubMed]
101. Fox-Robichaud A, Payne D, Hasan SU, Ostrovsky L, Fairhead T, Reinhardt P, et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest. 1998;101:2497–2505. [PMC free article] [PubMed]
102. Kubes P, Payne D, Grisham MB, Jourd-Heuil D, Fox-Robichaud A. Inhaled NO impacts vascular but not extravascular compartments in postischemic peripheral organs. Am J Physiol. 1999;277:H676–H682. [PubMed]
103. Ng ES, Jourd'heuil D, McCord JM, Hernandez D, Yasui M, Knight D, et al. Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion. Circ Res. 2004;94:559–565. [PubMed]
104. Cannon RO, III, Schechter AN, Panza JA, Ognibene FP, Pease-Fye ME, Waclawiw MA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108:279–287. [PMC free article] [PubMed]
105. Zuzak KJ, Schaeberle MD, Gladwin MT, Cannon RO, III, Levin IW. Noninvasive determination of spatially resolved and time-resolved tissue perfusion in humans during nitric oxide inhibition and inhalation by use of a visible-reflectance hyperspectral imaging technique. Circulation. 2001;104:2905–2910. [PubMed]
106. Rassaf T, Preik M, Kleinbongard P, Lauer T, Heiss C, Strauer BE, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest. 2002;109:1241–1248. [PMC free article] [PubMed]
107. Heiss C, Lauer T, Dejam A, Kleinbongard P, Hamada S, Rassaf T, et al. Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol. 2006;47:573–579. [PubMed]
108. Hogg N, Broniowska KA, Novalija J, Kettenhofen NJ, Novalija E. Role or S-nitrosothiol transport in the cardioprotective effects of S-nitrosocysteine in rat hearts. Free Radic Biol Med. 2007 [PubMed]
109. Funai EF, Davidson A, Seligman SP, Finlay TH. S-nitrosohemoglobin in the fetal circulation may represent a cycle for blood pressure regulation. Biochem Biophys Res Commun. 1997;239:875–877. [PubMed]
110. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA. 1992;89:7674–7677. [PubMed]
111. Wittenberg JB, Wittenberg BA. Myoglobin function reassessed. J Exp Biol. 2003;206:2011–2020. [PubMed]
112. Flogel U, Godecke A, Klotz LO, Schrader J. Role of myoglobin in the antioxidant defense of the heart. Faseb J. 2004;18:1156–1158. [PubMed]
113. Kumar D, Branch BG, Pattillo CB, Hood J, Thoma S, Simpson S, et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA. 2008;105:7540–7545. [PubMed]

Articles from Cardiovascular Research are provided here courtesy of Oxford University Press